Discover how IDDI biostatistics-driven RTSM helped the Sponsor to avoid serious imbalance between the two randomized arms for the treated patients.
SITUATION:
- A randomized Phase III trial to evaluate the efficacy and safety of a new drug to treat critical limb ischemia
- A randomized phase 3 study using a 2:1 minimization algorithm (with 0.8 as the probability) balancing the patients according to minimization factors between 2 arms (Active and Placebo)
CHALLENGES
- The treatment is only manufactured if the patient is randomized to Active arm. Treatment is using the bone marrow of the patient.
- If the product cannot be manufactured or is damaged during the transportation, the randomized patient will not be treated.
=> This caused serious imbalance between the two randomized arms for the treated patient
IDDI biostatistics-driven RTSM helped the Sponsor to avoid serious imbalance between the two randomized arms for the treated patients.
Read the case study now and contact us if you have any question!